Medicines Act 1981

The Medicines Act 1981 is a New Zealand Act about the manufacture, sale and supply of medicines, medical devices and related products. Its long title says it consolidates and amends the law relating to those areas.

For a business owner, the practical point is that this Act can affect the whole product journey. It may matter when you design a product, import it, label it, store it, advertise it, sell it, supply it or administer it.

The Act is administered by the Ministry of Health. It also works with regulations, notices, schedules and other instruments made under the Act, so the Act is the starting point rather than the only document you may need to check.

The Act can apply to a wide range of businesses. It is not limited to businesses that physically manufacture medicines. It can also catch businesses that import, pack, label, wholesale, retail, advertise, administer or otherwise deal with regulated products.

The interpretation section is detailed. It includes meanings for medicine, new medicine, prescription medicine, restricted medicine, medical device, therapeutic purpose and business. The Act also includes concepts such as herbal remedy, related product and animal remedy.

The definition of business is broad. It includes a professional practice and any activity carried on for reward. That means clinics and other health service businesses should not assume they are outside the Act just because they are service-based.

Your first compliance question is usually classification. The Act contains detailed definitions, and your own marketing label is not decisive. A product may fall within the Act because of what it is, what it is intended to do, or what you say it does.

The Act separately addresses medicines, new medicines, prescription medicines, restricted medicines and medical devices. It also deals with related products and includes exemptions for some situations, including specific exemptions relating to herbal remedies, practitioners, pharmacists, veterinarians, clinical trials and some other categories.

The meaning of therapeutic purpose matters. If your product claims point to curing, treating, preventing, diagnosing or otherwise affecting a condition, that can be a strong signal that medicines compliance needs checking.

Many businesses meet this Act through ordinary commercial decisions rather than a formal regulatory project. The trigger can arise well before first sale.

For example, importing stock, changing a formulation, relabelling a product, moving into wholesale supply, or rewriting ad copy can all change your compliance position. A product that was sold one way overseas may be treated differently in New Zealand.

Because of that, it is sensible to build a legal check into product launch and change management. Do not wait until stock is on the water or marketing is live.

The Act uses several different control tools. Businesses should keep them separate because one does not automatically satisfy another.

First, the Act states that manufacturers, wholesalers, packers of medicines, and operators of pharmacies are to be licensed. The Act then sets out applications for licences, grant of licences, effect and duration of licences, display of licences and the register of licences.

Second, the Act restricts the sale or supply of new medicines. It includes application pathways for the Minister's consent, including consent by verification, and also provides for provisional consent in some cases.

Third, medicines can be classified under the Act. The contents list confirms powers around classification, including section 106, which allows the Minister to classify medicines by notice in the Gazette.

The Act does more than regulate entry to market. It also controls how medicines are sold, supplied and used after that point.

The contents list shows provisions on sale of medicines by retail, administering prescription medicines, restrictions on possession of prescription medicines, restrictions on supply to particular persons, and powers of the Minister to prohibit prescribing and related conduct.

There is also a specific section on restrictions on sale of medical devices. That means businesses should not assume that once a product is in New Zealand it can be supplied through any channel or to any customer without further limits.

Not every restriction applies to every business. The exact rules depend on the product category, its classification, whether an exemption applies, and what your business is actually doing with the product.

The Act has a dedicated Part on medical advertisements. It includes restrictions on advertisements, further restrictions on advertisements, a requirement that advertisements contain the true name of the advertiser, and a rule on misleading branding.

The Act also deals with containers and packages of medicines, and it gives regulation-making powers over labels, package appearance and required label content. For many businesses, this is where risk appears first because marketing often moves faster than product compliance review.

Advertising issues can arise on websites, social media, brochures, conference material, packaging and point-of-sale material. Claims should be checked at the same time as classification, not after the campaign is approved internally.

The Act includes practical operational controls, not just approval rules. It contains provisions on records, custody of medicines, storage and delivery of medicines, and containers and packages.

It also places a duty on importers and manufacturers to report untoward effects of medicines. In addition, importers and manufacturers must have and produce specifications of medicines.

These duties matter in day-to-day operations. If your business uses a warehouse, third-party logistics provider, contract packer or relabelling service, your compliance system should cover handling and documentation as well as legal status.

The Act gives officers significant enforcement powers. This is especially important for importers.

Where an officer takes a sample from an imported consignment reasonably believed to be a medicine, the officer must notify the importer. An officer may direct Customs to detain the rest of the consignment until analysis or examination is completed.

The goods may sometimes be moved to a specified place at the importer's expense if the importer gives a written undertaking to detain them while results are obtained or examination is completed.

If, after analysis or examination, an officer reasonably believes the consignment does not comply with the Act or regulations, the officer may seize and detain the goods, order them returned outside New Zealand at the importer's expense, or release them subject to conditions, including relabelling conditions.

This Act is detailed and product-specific. The right compliance answer depends on both the product category and the business activity. Before relying on a high-level summary, work through the exact trigger points that apply to your product.

In practice, most businesses should check the Act itself, any relevant regulations, any current classification instruments, and the exact pathway they are using for import, manufacture, sale, supply or advertising.

The Act is in force. The official consolidated version states it is the latest version as at 19 November 2025.

The Act received assent on 23 October 1981. Section 1 notes that the Act came into force on a date appointed by Order in Council, and the official note states that the Act, except section 21(1)(a), was brought into force on 1 August 1984 by the Medicines Act Commencement Order 1984.

The Act has been amended many times. If your business is working on a live product launch or import, check the current version and any relevant secondary legislation before acting.